Neil Cashman - 07 Jul 2022 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
Chief Scientific Officer, Director
Signature
/s/ Jason L. Langford, Attorney-in-Fact for Neil R. Cashman
Issuer symbol
PMN
Transactions as of
07 Jul 2022
Net transactions value
$0
Form type
3
Filing time
07 Jul 2022, 19:24:44 UTC
Next filing
25 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMN Common Shares 102,661 07 Jul 2022 Direct
holding PMN Common Shares 1,617 07 Jul 2022 By his spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMN Option (right to buy) 07 Jul 2022 Common Shares 78,822 $2.43 Direct F1, F2
holding PMN Option (right to buy) 07 Jul 2022 Common Shares 36,988 $3.90 Direct F1, F3
holding PMN Option (right to buy) 07 Jul 2022 Common Shares 50,000 $8.40 Direct F1, F4
holding PMN Warrants (right to buy) 07 Jul 2022 Common Shares 8,333 $21.00 Direct F1
holding PMN Warrants (right to buy) 07 Jul 2022 Common Shares 3,472 $12.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Conversion or exercise price is in Canadian dollars.
F2 The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on July 6, 2015.
F3 The option agreement provides that the option vested 1/4 immediately with the balance vesting ratably over 36 months. The option was granted on July 31, 2015.
F4 The option agreement provides that the options become exercisable in 48 equal monthly installments beginning one month after the grant. The option was granted on February 10, 2022.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney